CN101610997A - 用作金属蛋白酶抑制剂的具有芳基-磺酰氨结构的化合物 - Google Patents

用作金属蛋白酶抑制剂的具有芳基-磺酰氨结构的化合物 Download PDF

Info

Publication number
CN101610997A
CN101610997A CNA200880004727XA CN200880004727A CN101610997A CN 101610997 A CN101610997 A CN 101610997A CN A200880004727X A CNA200880004727X A CN A200880004727XA CN 200880004727 A CN200880004727 A CN 200880004727A CN 101610997 A CN101610997 A CN 101610997A
Authority
CN
China
Prior art keywords
group
compound
formula
alkyl
straight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200880004727XA
Other languages
English (en)
Chinese (zh)
Inventor
A·洛赛罗
E·努提
E·奥兰蒂尼
A·巴尔萨莫
T·图克希纳迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Imaging SpA
Original Assignee
Bracco Imaging SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging SpA filed Critical Bracco Imaging SpA
Publication of CN101610997A publication Critical patent/CN101610997A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
CNA200880004727XA 2007-03-19 2008-03-14 用作金属蛋白酶抑制剂的具有芳基-磺酰氨结构的化合物 Pending CN101610997A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104393A EP1972617A1 (en) 2007-03-19 2007-03-19 Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
EP07104393.9 2007-03-19

Publications (1)

Publication Number Publication Date
CN101610997A true CN101610997A (zh) 2009-12-23

Family

ID=38626433

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200880004727XA Pending CN101610997A (zh) 2007-03-19 2008-03-14 用作金属蛋白酶抑制剂的具有芳基-磺酰氨结构的化合物

Country Status (12)

Country Link
US (1) US8329751B2 (cg-RX-API-DMAC10.html)
EP (2) EP1972617A1 (cg-RX-API-DMAC10.html)
JP (1) JP2010521529A (cg-RX-API-DMAC10.html)
KR (1) KR20090121329A (cg-RX-API-DMAC10.html)
CN (1) CN101610997A (cg-RX-API-DMAC10.html)
AU (1) AU2008228260B2 (cg-RX-API-DMAC10.html)
CA (1) CA2680239A1 (cg-RX-API-DMAC10.html)
IL (1) IL200951A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009009409A (cg-RX-API-DMAC10.html)
RU (1) RU2488580C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008113756A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200905263B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
EP2149568A1 (en) 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
WO2024102810A1 (en) 2022-11-08 2024-05-16 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5058026A (cg-RX-API-DMAC10.html) * 1973-09-26 1975-05-20
PL342009A1 (en) * 1998-02-04 2001-05-07 Novartis Ag Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases
RU2217418C2 (ru) * 1998-04-03 2003-11-27 Санкио Компани, Лимитед Сульфонамидное производное, лекарственное средство, способы лечения
WO2006101828A1 (en) * 2005-03-15 2006-09-28 Bayer Cropscience Ag Insecticidal alkylamino phenyl sulfonamide derivatives

Also Published As

Publication number Publication date
MX2009009409A (es) 2009-09-14
JP2010521529A (ja) 2010-06-24
WO2008113756A8 (en) 2008-11-06
EP2121590A2 (en) 2009-11-25
US20100087505A1 (en) 2010-04-08
IL200951A0 (en) 2010-05-17
US8329751B2 (en) 2012-12-11
RU2488580C2 (ru) 2013-07-27
EP1972617A1 (en) 2008-09-24
AU2008228260A1 (en) 2008-09-25
AU2008228260B2 (en) 2012-11-22
WO2008113756A3 (en) 2008-12-18
KR20090121329A (ko) 2009-11-25
RU2009138346A (ru) 2011-04-27
CA2680239A1 (en) 2008-09-25
WO2008113756A2 (en) 2008-09-25
ZA200905263B (en) 2010-06-30

Similar Documents

Publication Publication Date Title
KR100432602B1 (ko) 매트릭스메탈로프로테아제억제제
KR0143565B1 (ko) 피발산의 p-치환된 페닐 에스테르 유도체, 그의 제조 방법 및 이를 포함하는 조성물.
US5859061A (en) Bis-sulfonamides hydroxamic acids as MMP inhibitors
JP2002504916A (ja) 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
JP2002503720A (ja) マトリックス分解メタロプロテイナーゼを阻害するスルホニルアミノ誘導体
JP4150597B2 (ja) スルホンアミド誘導体
HRP970474A2 (en) Compounds for and a method of inhibiting matrix metalloproteinases
EP0925289A1 (en) Matrix metalloproteinase inhibitors
US6900194B1 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
US6518267B1 (en) Protease inhibitors
HUP0100277A2 (hu) 2,3,4,5-Tetrahidro-1H-[1,4]benzodiazepin-3-hidroxámsav-származékok mint metalloproteináz inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AU2003297364B2 (en) Inhibitors of TACE
CN101568521A (zh) 硫代芳基取代的锌蛋白酶抑制剂和它们的用途
PL198827B1 (pl) ω-Amidy N-arylosulfonyloaminokwasów, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie ω-amidów N-arylosulfonyloaminokwasów
RU2488580C2 (ru) Соединения, имеющие арилсульфонамидную структуру, применимые в качестве ингибиторов металлопротеаз
JP2003524008A (ja) アリールピペラジンおよびアリールピペリジン、およびそれらのメタロプロテイナーゼ阻害剤としての使用
US20040138206A1 (en) Novel sulfonamide derivatives, intermidiate thereof, its preparation methods, and pharmaceutical composition comprising the same
US6482827B1 (en) Matrix metalloproteinase inhibitors
JP2003212837A (ja) アミジノ誘導体並びにそれを用いた抗血液凝固剤および血栓症治療剤
KR20010034168A (ko) 매트릭스 메탈로프로테이나제 억제제
JPH0753500A (ja) グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JP2002523486A (ja) N−ヒドロキシアシルアミノ化合物、それらの製造方法、およびそれらを含む医薬組成物
JP2003524007A (ja) アリールピペラジン類およびそれらのメタロプロテイナーゼ阻害剤(mmp)としての使用
CN102105456A (zh) 作为金属蛋白酶抑制剂的芳基-磺酰胺二聚体
TW580491B (en) Aryl-S(O)n-substituted hydroxamic acids, and their preparation and use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091223